Feature | January 14, 2013

Oslo Breast Cancer Screening Trial Concludes Use of 3-D With 2-D Exam Finds Significantly More Cancers

Hologic Inc. Radiology RSNA 3-D Mammography Clinical Study

January 14, 2013 — Hologic Inc. announced that a groundbreaking new clinical study published in Radiology, the Radiological Society of North America scientific journal, found that the addition of three dimensional (3-D) mammography (breast tomosynthesis) screening technology to a 2-D breast screening exam significantly increased cancer detection while reducing the number of false positives.

The study, "Comparison of Digital Mammography Alone and Digital Mammography plus Tomosynthesis in a Population-based Screening Program," was led by Per Skaane, M.D., Ph.D. of Oslo University Hospital Ullevaal. The study was based on 12,631 screening examinations in a large hospital in Norway.

The researchers using Hologic's 3-D mammography technology in combination with a 2-D mammogram found a significant increase in cancer detection rates, particularly for invasive cancers, and a simultaneous decrease in false-positive rates compared with 2-D mammography alone. Significant findings include:

  • A 40 percent increase in the detection of invasive breast cancers
  • A 27 percent increase in the detection of all cancers (invasive and in situ cancers combined)
  • A 15 percent decrease in false-positive rates

The authors reported that the increase in cancer detection was found across all breast tissue densities, from dense to fatty. At the same time, there was no increase in the detection of ductal carcinoma in situ (DCIS), which is non-invasive and cited by critics of mammography screening as potentially being over-diagnosed.

As a result of the large increase in the detection of invasive cancers rather than in situ cancers the authors of the paper state, "Perhaps our most important observation is that with the mammography-plus-tomosynthesis arm, the actual benefit, in terms of possibly improving outcome owing to earlier detection, may be larger than merely the difference in the total count or number of detected cancers."

Rob Cascella, Hologic's president and chief executive iofficer said, "A number of major papers demonstrating the value of 3-D mammography have been published in the last few months. The Oslo trial is the first large-scale prospective study to show the additional cancers found with 3-D mammography in combination with 2-D mammography were invasive cancers — the very type of cancers we want to detect and treat early. Three-dimensional mammography is the best breast screening technology to date in that it finds significantly more invasive cancers while also reducing false positives. Most other imaging technologies for screening require users to compromise specificity (recall rate) for sensitivity (cancer detection). We believe the value of 3-D mammography in breast cancer screening is most compelling."

Three-dimensional mammography was approved for clinical use for breast cancer screening and diagnosis in the United States in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic's 3-D mammography technology is in use in 47 states and 30 countries outside the United States. Unlike a screening 2-D digital mammogram, which involves a single X-ray image of the breast, 3-D mammography captures multiple, low-dose images from multiple angles around the breast. The images are then used to produce a 3-D reconstruction of the breast.

Skaane and his research team in Oslo are well known for their research. Their Oslo I and Oslo II trials were important studies comparing 2-D digital mammography to screen-film for the detection of breast cancer.

The study was published online in advance of print on the Radiology website.

For more information: www.hologic.com/investors-overview

Related Content

Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
DenseBreast-info.org Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Breast imaging X-ray mammogram showing a breast tumor. Photo courtesy of Monthian Ritchan-Ad

Photo courtesy of Monthian Ritchan-Ad

Feature | Breast Density | September 08, 2017 | By Roy Prager, M.D.
While mammograms play a vital role in efforts to identify breast cancer, they can present some challenges in women with...
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Musculoskeletal Extremity Imaging in Medicare Beneficiaries Increased Over Two Decades
News | Orthopedic Imaging | September 06, 2017
A new study by the Harvey L. Neiman Health Policy Institute found that in the Medicare population, the utilization...
FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
September 6, 2017 — Guerbet LLC USA announced that the U.S.
Overlay Init